A study testing whether a GLP-1 medicine can help people ease psoriatic arthritis.

Recruiting now. Registry record last updated August 10, 2026.

Who can join: Adults 18+, have psoriatic arthritis.
What you take: Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts: The full study runs about 2 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor Medical College of WisconsinDrug GLP-1 agonistsClass OtherSites 1 USEnrollment target 22

What this study is for

Primary condition: Psoriatic Arthritis (PsA).

Full scientific study title: Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial.

Who can join

Age18 and upSexAny

Adults 18+, have psoriatic arthritis. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Adult patients (age 18 and older) who present to rheumatology clinic
Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB).
Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA
Participants must have a Body Mass Index (BMI) of 30 kg/m\^2
Participants must be treated for PsA in accordance with guidelines

Key exclusion criteria

Any prior use of GLP-1 agonists
Inability to provide informed consent
Current participation in another PsA study
Treatment initiation by GLP-1 agonists contraindicated by FDA
Patients with hemoglobin A1c (HbA1c) \> 10 at baseline

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Wisconsin1 site

Medical College of Wisconsin/Froedtert Hosptial
Milwaukee, Wisconsin
Shikha Singla, MD414-955-7040ssingla@mcw.edu

Follow this trial

We email you if NCT07111494 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: May 1, 2026. Expected completion: October 15, 2028. Last updated on ClinicalTrials.gov: August 10, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.